This webinar will summarize the Sunshine Act or Open Payments Program requirements and provide practical solutions to the most common situations that are prevalent and necessary between sponsors and investigators.
The Sunshine Act or Open Payments Program requires manufacturers of drugs, medical devices, and biologics that participate in U.S. federal health care programs to report certain clinical investigator payments and items of value given to physicians and teaching hospitals. This Act was part of a healthcare reform bill adopted in March 2010. It came about due to requests for increased transparency about the financial relationships between physicians and the industry.
WHY SHOULD YOU ATTEND?
The Sunshine Act exposes the physicians and sponsors to new clinical trial reporting requirements and detail non-compliance which would lead to hefty fines. Templates for reporting format, exemptions to reporting requirements, and timelines for compliance and enforcement will be discussed.
AREA COVERED
Life science companies face the challenge of implementing the detailed reporting required by the Act as healthcare providers determine how to use their own data to anticipate public reporting of payments by life science companies to physicians and teaching hospitals.
This webinar will examine the implications of the Sunshine Act for healthcare providers and life science companies and discuss practical steps they can take to implement the Act and prepare for transparency.
- Purpose of the Sunshine Act
- Who is required to report under the Sunshine Act?
- What is reported?
- Exclusions
- Tracking
- Penalties
- Useful links
WHO WILL BENEFIT?
- Manufacturers of FDA-regulated products: Drug, Medical Device, and Biotech Companies
- Clinical Trial Professionals such as Project Managers, CRAs, Medical Writers
- Senior Management for Companies developing new products for the US market
- Regulatory Affairs Professionals
- People investing in FDA-regulated products intended for the US market
The Sunshine Act exposes the physicians and sponsors to new clinical trial reporting requirements and detail non-compliance which would lead to hefty fines. Templates for reporting format, exemptions to reporting requirements, and timelines for compliance and enforcement will be discussed.
Life science companies face the challenge of implementing the detailed reporting required by the Act as healthcare providers determine how to use their own data to anticipate public reporting of payments by life science companies to physicians and teaching hospitals.
This webinar will examine the implications of the Sunshine Act for healthcare providers and life science companies and discuss practical steps they can take to implement the Act and prepare for transparency.
- Purpose of the Sunshine Act
- Who is required to report under the Sunshine Act?
- What is reported?
- Exclusions
- Tracking
- Penalties
- Useful links
- Manufacturers of FDA-regulated products: Drug, Medical Device, and Biotech Companies
- Clinical Trial Professionals such as Project Managers, CRAs, Medical Writers
- Senior Management for Companies developing new products for the US market
- Regulatory Affairs Professionals
- People investing in FDA-regulated products intended for the US market
Speaker Profile

Danielle DeLucy, MS, is owner of ASA Training and Consulting, LLC which provides Pharmaceutical and Biologics based companies with training and quality systems assistance in order to meet Regulatory compliance. Prior to this role, Danielle has been in the industry for 15 years serving in numerous Quality Management Roles, such as the Director of Product Quality, the oversight of Sterility Assurance practices and provided QA oversight of numerous filling and packaging operations. Danielle began her QA career as a Quality Control Pharmaceutical Microbiologist at a contract laboratory where she performed various tests for their clients. In the years after, she …
Upcoming Webinars

Project Management for Non-Project Managers - Scheduling yo…

Imposter Syndrome: How to Define, Understand & Shift Your E…

Contractor vs Employee: How to Tell the Difference and What…

FDA current recommendations related to timely initiation of…

Complying with the NEW I-9 and E-Verify Regulations - The I…

Impact Assessments For Supplier Change Notices

Implicit Bias: Becoming Aware of Your Inner Storyteller


The Federal Anti-Kickback Statute & Stark Law: What Physici…

Building an Effective Injury Management Process

Fatal Errors Employers Make When Updating Employee Handbook…

From Awareness to Action: Going Beyond the Law in Preventin…

Understanding the Changes Coming to NCCI's Experience Mod i…

Onboarding is NOT Orientation - How to Improve the New Empl…


From Awareness to Action: Going Beyond the Law in Preventin…

FDA Compliance and Clinical Trial Computer System Validation


5 Proven Ways To Engage & Retain Your Team Even During The …


Navigating New Paths: Unveiling Your Unique Abilities for a…

Form 1099 Update 2023: Latest Forms, Rules and Reporting Re…


Strategic Interviewing & Selection: Getting the Right Talen…



Excel - Unleashing the Full Potential of New Functions (Exc…

Amazing (!) AI Tools For Building Your Business

Implementing a Robust Change Control Program - Key Elements…


How to Conduct Annual Product Reviews to Achieve GMP Compli…


What Business Leaders Need to Know About Cybersecurity Prep…

Harassment, Bullying, Gossip, Confrontational and Disruptiv…

Understanding Social Security and Optimizing Retirement Inc…

Human Connection Leadership in 3D: Dare. Dream. Deliver.